Is cbdMD Inc (YCBD) overvalued? · P/E 0.3, rev $19.5M
cbdMD Inc (YCBD) is a drug manufacturers - specialty & generic company listed on AMEX.
This page asks whether cbdMD Inc (YCBD) looks expensive on cached numbers — not a short thesis.
Latest reported YCBD revenue for 2024-09-30 was $19.5M. Net income was -$152.8K. Revenue was down 19.3% from 2023-09-30 to 2024-09-30. YCBD currently screens at market cap $7.2M and trailing P/E 0.3.
YCBD currently screens at market cap $7.2M and trailing P/E 0.3. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next YCBD 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the YCBD stock page for the full model, not this heading.
Not investment advice.